

Biologically active marine natural products


Kenneth L. Rinehart

Roger Adams Laboratory, University of Illinois at Urbana-Champaign,
 Urbana, Illinois 61801, USA



Abstract - Sponges, tunicates, and other species from shallow and deep-sea habitats yield antiviral, antitumor, antimicrobial, and antifouling compounds, as well as cytotoxic and immunomodulatory agents; our structure assignments and synthetic work are reviewed. Didemnin B, from a colonial tunicate, is in Phase II clinical trials in the United States and has been synthesized along with related compounds, including stereoisomers, whose bioactivity is compared.

The search for biologically active marine natural products has expanded horizontally (to new sites) and vertically (to deeper water). In collaboration with Harbor Branch Oceanographic Institution, Inc./SeaPharm Project we have recently undertaken an investigation of a number of sponges collected at depths of 30 to 800 meters and demonstrated in the field to give biologically active extracts (ref. 1). Some of the compounds isolated from a few of these deep-water sponges are shown in Scheme 1. While most of the pharmacological activities ascribed to the compounds have not been reported previously and the sources of the sponges as well as nearly all the sponge species themselves are novel, the compounds are generally either known or of recognized types. An example is provided by compounds isolated from a new genus (a *Goreauiella* species) collected at -698 m; these proved to be oroidin and odiline, previously obtained from other genera of shallow-water sponges (refs. 2-4). Similarly, the new compounds topsentin and bromotopsentin, obtained from a sponge collected in the Caribbean at -174 to -360 m, were isolated simultaneously from a shallow-water Mediterranean sponge (refs. 5,6).

Scheme 1



Scheme 3



Trididemnum solidumAgelas coniferin

(Scheme 3) resulting from putative $4\pi + 2\pi$ (Diels-Alder) cyclization, which contrasts with the apparent $2\pi + 2\pi$ cyclization involved in sceptrin formation (refs. 19-21). Structure studies of these compounds involved both FABMS/MS and LC/FABMS techniques (ref. 22). The sceptrins and ageliferins all show antiviral activity and influence barnacle settling.

Considerably more potent antifouling activity has been demonstrated for the renillafoulin from Renilla reniformis, a sea pansy (Scheme 4). Discovered at the Duke University Marine Laboratory, these compounds were purified and assigned structures in Illinois (ref. 23).

A compound with potent (though non-therapeutic) biological activity recently studied in our laboratory is the hepatotoxin nodularin (Scheme 4) from the cyanobacterium Nodularia spumigena. This study involved collaboration with the University of Canterbury, the University of Illinois College of Veterinary Medicine, and Wright State University (ref. 24). The structure assignment required extensive use of HRFABMS and FABMS/MS. The characteristic C_{20} amino acid unit Adda also occurs in the microcystins (cyanoginosins) (refs. 25,26). In connection with our study of nodularin we assigned the absolute stereochemistry of Adda as $2S,3S,8S,9S$ (ref. 24) and synthesized the parent molecule and protected derivatives.

Scheme 4

Nodularia spumigenaRenilla reniformis

Renillafoulin A, B, C
(antifouling)

$R^1 = R^2 = \text{Ac-}$
 $R^1 = \text{Ac}, R^2 = \text{C}_2\text{H}_5\text{CO-}$
 $R^1 = \text{Ac}, R^2 = \text{n-C}_7\text{H}_{15}\text{CO-}$

Acknowledgements In addition to my colleagues named in the references cited, I should like to acknowledge the efforts of Drs. Shinji Tsujii and Ashok D. Patil for the work on deep-water sponges. Work at the University of Illinois was supported in part by grants from the National Institute of Allergy and Infectious Diseases (AI04769, AI01278) and by a contract with the Harbor Branch Oceanographic Institution. The Mass Spectrometry Laboratory of the School of Chemical Sciences is supported in part by a grant from the National Institute of General Medical Sciences (GM27029).

REFERENCES

1. K.L. Rinehart, Jr., J.E. Armstrong, R.G. Hughes, Jr., W.C. Thiess, M.H.G. Munro, T.G. Holt, H. Hummel, and S.A. Pomponi, IUPAC Vth International Symposium on Marine Natural Products, Paris, Sep. 2-6, Paper C:25.
2. E.E. Garcia, L.E. Benjamin, and R.I. Fryer, J. Chem. Soc. Chem. Commun., 78-79 (1973).
3. G. De Nanteuil, A. Ahond, J. Guilhem, C. Poupat, E.T.H. Dau, P. Potier, M. Pusset, J. Pusset, and P. Laboute, Tetrahedron, 41, 6019-6033 (1985).
4. K.F. Albizzati and D.J. Faulkner, J. Org. Chem., 50, 4163-4164 (1985).
5. K. Bartik, J.-C. Braekman, D. Daloz, C. Stoller, J. Huysecom, G. Vandevyver, and R. Ottinger, Can. J. Chem., 65, 2118-2121 (1987).
6. S. Tsujii, K. L. Rinehart, S.P. Gunasekera, S.S. Cross, M.S. Lui, S.A. Pomponi, and M.C. Diaz, submitted.
7. K.L. Rinehart, Jr., et al., Pure Appl. Chem., 53, 795-817 (1981).
8. M.M. Sigel, L.J. McCumber, J.A. Hightower, S.S. Hayasaka, E.M. Huggins, Jr., and J.F. Davis, Am. Zool., 23, 221-227 (1983).
9. L.H. Li, The Upjohn Company, Kalamazoo, MI, personal communication.
10. K.L. Rinehart, Jr., and T.G. Holt, U.S. Patent Application Serial No. 006,395, Jan. 23, 1987.
11. K.L. Rinehart, Jr., J. Kobayashi, G.C. Harbour, J. Gilmore, M. Mascal, T.G. Holt, L.S. Shield, and F. Lafargue, J. Am. Chem. Soc., 109, 3378-3387 (1987).
12. K.L. Rinehart, Jr., U.S. Patent Nos. 4,493,796, Jan. 15, 1985, and 4,548,814, Oct. 22, 1985.
13. K.L. Rinehart, in Proceedings, 10th Am. Peptide Symposium, St. Louis, MO, May 23-28, 1987, ESCOM Science Publishers, The Netherlands, 1988, pp 626-631.
14. K.L. Rinehart, Jr., G.C. Harbour, and J. Kobayashi, U.S. Patent No. 4,631,149, Dec. 23, 1986.
15. K.L. Rinehart, V. Kishore, K.C. Bible, R. Sakai, D.W. Sullins, and K.-M. Li, J. Nat. Prod., 51, 1-21 (1988).
16. K.L. Rinehart, Jr., V. Kishore, S. Nagarajan, R.J. Lake, J.B. Gloer, F.A. Bozich, K.-M. Li, R.E. Maleczka, Jr., W.L. Todsén, M.H.G. Munro, D.W. Sullins, and R. Sakai, J. Am. Chem. Soc., 109, 6846-6848 (1987).
17. K.C. Bible, M. Buytendorp, P.D. Zierath, and K.L. Rinehart, Proc. Natl. Acad. Sci. USA 85, 0000 (July 1988).
18. R.P. Walker, D.J. Faulkner, D. VanEngen, and J. Clardy, J. Am. Chem. Soc., 103, 6772-6773 (1981).
19. P.A. Keifer, Ph.D. Dissertation, University of Illinois at Urbana-Champaign, Urbana, 1986.
20. P.A. Keifer, M.E.S. Koker, R.E. Schwartz, R.G. Hughes, Jr., D. Rittschof, and K.L. Rinehart, 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Sep. 28-Oct. 1, 1986, No. 1281.
21. K.L. Rinehart, Jr., U.S. Patent No. 4,737,510, Apr. 12, 1988.
22. J.G. Stroh, K.L. Rinehart, Jr., J.C. Cook, T. Kihara, M. Suzuki, and T. Arai, J. Am. Chem. Soc., 106, 858-859 (1986).
23. P.A. Keifer, K.L. Rinehart, Jr., and I.R. Hooper, J. Org. Chem., 51, 4450-4454 (1986).
24. K.L. Rinehart, K.-I. Harada, M. Namikoshi, C. Chen, C.A. Harvis, M.H.G. Munro, J.W. Blunt, P.E. Mulligan, V.R. Beasley, A.M. Dahlem, and W.W. Carmichael, submitted.
25. D.P. Botes, P.L. Wessels, H. Kruger, M.T.C. Runnegar, S. Santikarn, R.J. Smith, J.C.J. Barna, and D.H. Williams, J. Chem. Soc., Perkin Trans. I, 2747-2748 (1985).
26. P. Painuly, R. Perez, T. Fukai, and Y. Shimizu, Tetrahedron Lett., 29, 11-14 (1988).